About Alexza Pharmaceuticals (NASDAQ:ALXA)
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:ALXA
- CUSIP: N/A
- Web: www.alexza.com/
- 50 Day Moving Avg: $0.94
- 200 Day Moving Avg: $0.94
- 52 Week Range: $0.43 - $1.03
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.80
- P/E Growth: 0.00
- Net Margins: -466.94%
- Return on Assets: -106.54%
Frequently Asked Questions for Alexza Pharmaceuticals (NASDAQ:ALXA)
What is Alexza Pharmaceuticals' stock symbol?
Alexza Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXA."
How were Alexza Pharmaceuticals' earnings last quarter?
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.72 million for the quarter. View Alexza Pharmaceuticals' Earnings History.
Who are some of Alexza Pharmaceuticals' key competitors?
Some companies that are related to Alexza Pharmaceuticals include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Stryker (SYK), Becton Dickinson and Co (BDX), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), NMC Health PLC (NMC), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI) and Alere (ALR).
How do I buy Alexza Pharmaceuticals stock?
Shares of Alexza Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexza Pharmaceuticals' stock price today?
MarketBeat Community Rating for Alexza Pharmaceuticals (NASDAQ ALXA)MarketBeat's community ratings are surveys of what our community members think about Alexza Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Alexza Pharmaceuticals stock can currently be purchased for approximately $0.94.
Consensus Ratings for Alexza Pharmaceuticals (NASDAQ:ALXA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Analysts' Ratings History for Alexza Pharmaceuticals (NASDAQ:ALXA)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Alexza Pharmaceuticals (NASDAQ:ALXA)Earnings History by Quarter for Alexza Pharmaceuticals (NASDAQ ALXA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/28/2016||Q415||($0.37)||($0.15)||$1.45 million||$0.67 million||View||Listen|
|11/5/2015||Q315||($0.34)||($0.27)||$1.60 million||$1.77 million||View||N/A|
|8/6/2015||Q215||($0.66)||($0.63)||$2.31 million||$1.88 million||View||N/A|
|5/6/2015||Q115||($0.51)||($0.02)||$2.23 million||$0.71 million||View||N/A|
|3/9/2015||Q414||($0.80)||($0.50)||$2.99 million||$1.45 billion||View||N/A|
|8/7/2014||Q2||($0.67)||($0.62)||$2.24 million||$1.50 million||View||Listen|
|5/5/2014||Q1||($0.55)||($0.55)||$2.36 million||$2.17 million||View||Listen|
|8/8/2013||Q2 2013||$0.09||($0.21)||$14.17 million||$40.84 million||View||Listen|
|5/9/2013||Q1 2013||($0.45)||($1.31)||$1.00 million||$0.73 million||View||Listen|
Earnings Estimates for Alexza Pharmaceuticals (NASDAQ:ALXA)
Current Year EPS Consensus Estimate: $-2.11 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS
Dividend History for Alexza Pharmaceuticals (NASDAQ:ALXA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alexza Pharmaceuticals (NASDAQ:ALXA)Insider Trades by Quarter for Alexza Pharmaceuticals (NASDAQ:ALXA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/21/2016||Ferrer Internacional S Grupo||Major Shareholder||Buy||19,465,714||$0.90||$17,519,142.60|| |
|9/6/2013||Gordon Ringold||Director||Buy||10,000||$4.77||$47,700.00|| |
|7/26/2013||Thomas Braxton King||CEO||Buy||40,000||$4.48||$179,200.00|| |
|7/26/2013||Thomas Braxton King||CEO||Buy||40,000||$4.48||$179,200.00|| |
|1/18/2013||Lansdowne Partners Austria Gmb||Major Shareholder||Sell||125,000||$4.75||$593,750.00|| |
|12/27/2012||Lansdowne Partners Austria Gmb||Major Shareholder||Buy||72,189||$4.85||$350,116.65|| |
|12/26/2012||James V Cassella||EVP||Sell||4,558||$4.90||$22,334.20|| |
Headline Trends for Alexza Pharmaceuticals (NASDAQ:ALXA)
Latest Headlines for Alexza Pharmaceuticals (NASDAQ:ALXA)
|Comparing Alexza Pharmaceuticals (ALXA) & Endo International PLC (ENDP)|
www.americanbankingnews.com - July 23 at 12:14 PM
|Alexza Pharmaceuticals (NASDAQ:ALXA) versus Endo International PLC (ENDP) Head-To-Head Comparison|
www.americanbankingnews.com - July 19 at 8:42 PM
|Alexza Pharmaceuticals (NASDAQ:ALXA) versus Endo International PLC (ENDP) Head to Head Review|
www.americanbankingnews.com - July 14 at 10:54 AM
|Head-To-Head Review: Alexza Pharmaceuticals (ALXA) versus Endo International PLC (ENDP)|
www.americanbankingnews.com - July 2 at 7:54 AM
|Grupo Ferrer to Acquire Alexza Pharma (ALXA) for 90c/Share|
www.streetinsider.com - June 22 at 3:27 PM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisti|
biz.yahoo.com - June 21 at 8:55 AM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or|
biz.yahoo.com - June 16 at 4:10 PM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - May 13 at 4:04 PM
|Q1 2016 Alexza Pharmaceuticals Inc Earnings Release - After Market Close|
biz.yahoo.com - May 11 at 7:07 AM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material|
biz.yahoo.com - May 10 at 6:15 AM
|Worst Performing Industries For April 26, 2016 - Benzinga|
www.benzinga.com - April 26 at 12:10 PM
|Q4 2015 Alexza Pharmaceuticals Inc Earnings Release - After Market Close|
biz.yahoo.com - March 28 at 7:07 AM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements an|
biz.yahoo.com - March 24 at 4:14 PM
|Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding LoI - Benzinga|
www.benzinga.com - February 28 at 2:01 PM
|Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter Of Intent|
www.thestreet.com - February 26 at 8:55 PM
|Alexza Pharma (ALXA) Reacquires ADASUVE Rights from Teva - StreetInsider.com|
www.streetinsider.com - February 24 at 2:40 PM
|ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi|
biz.yahoo.com - February 24 at 9:09 AM
Alexza Pharmaceuticals (ALXA) Chart for Thursday, October, 19, 2017